| Abstrakt: |
Microdilution susceptibility tests were performed with 527 clinical isolates collected from seven geographically separate institutions: 60% of the strains demonstrated some β-lactamase activity, as detected by nitrocefin hydrolysis. Sch 29482 (SCH) was very resistant to hydrolysis by six different β-lactmäases and was effective against all β-lactamase-producing isolates, except Pseudomonas aeruginosa. SCH was more effective than the oral agents, amoxycillin, cephalexin, or cefaclor and the parenterally administered β-lactams, cephalothin or cefamandole. Its spectrum of activity was most similar to that of cefotaxime. SCH had no activity against Pseudomonas species other than Ps. cepacia and Ps. acidovorans. It was minimally active against Streptococcus faecalis and methicillin-resistant Staphylococcus aureus, but very active against methicillin-susceptible Staph. aureus, Str. pyogenes, Str. pneumoniae, Neisseria meningitidis, N. gonorrhoeae, and Haemophilus influenzae. All but 3 of 218 Enterobacteriaceae strains were inhibited by 80 mg/l. In-vitro activity of SCH was markedly diminished when tested in the presence of 50% human serum. In addition to being β-lactamase stable, SCH markedly inhibited the activity of Type I β-lactamase and partially inhibited Type III (TEM 1 and TEM 2) enzymes. [ABSTRACT FROM PUBLISHER] |
